ClinicalTrials.gg
Active, not recruitingNCT03220022Updated Nov 18, 2026Results posted

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

A Phase 1 interventional study of Cyclophosphamide and Doxorubicin Hydrochloride in AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma and Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 19 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Lymphoma, AIDS-Related with a site in United States — none open to participants now, 1 under way, none of them phase 3. Lymphoma, AIDS-Related · United States.

Started
2018
the only one that year
Phase 1
Only one
of the 12
Registered
11th of 12
by date
Lead sponsor
5 of 12
National Cancer Institute (NCI)

Among the 12 studies in Lymphoma, AIDS-Related with a site in United States, this one is the only one that started in 2018, is the only one in phase 1, and was the 11th registered.

Lymphoma, AIDS-Related

25 studies on the registry are indexed under Lymphoma, AIDS-Related; 2 are open to participants now.

Browse Lymphoma, AIDS-Related studies →

Open to participants now

None of the 12 studies in Lymphoma, AIDS-Related with a site in United States is open now. The open studies under Lymphoma, AIDS-Related, anywhere →

Who these studies take

Of the 2 Lymphoma, AIDS-Related studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Lymphoma, AIDS-Related with a site in United States as a file.
02

Study summary

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the safety and tolerability of ibrutinib and rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) in participants with acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL).

SECONDARY OBJECTIVES:

I. To evaluate the complete response (CR) rates of ARL to ibrutinib and R-da-EPOCH.

II. To measure the 1-year and 2-year overall and progression-free survival of participants with ARL treated with combination ibrutinib and R-da-EPOCH, including preliminary comparison of non-germinal center B-cell (GCB) with historical controls treated with R-da-EPOCH.

III. To categorize and compare the cell-of-origin by gene expression profiling (GEP) gene expression-based classification (GCB, activated B-cell-like, unclassifiable) to immunohistochemistry (IHC) classification (GCB, non-GCB), estimate the discordant classification, and correlate each biological classification (IHC and GEP) with treatment response rates and survival.

IV. To calculate the percentage of participants who receive two or more cycles of R-da-EPOCH, and are able to continue on a minimum dose level of cyclophosphamide of -1 and above after dose adjustments for hematologic toxicities.

V. To determine the average number of days per cycle participants are able to stay on planned dose of ibrutinib at the recommended phase II dose (RP2D).

VI. To assess the effect of ibrutinib and R-da-EPOCH on levels of circulating tumor deoxyribonucleic acid (DNA).

VII. To assess the effect and degree of ibrutinib and R-da-EPOCH on T-cell receptor signaling via ITK inhibition.

VIII. To assess the effect of ibrutinib and R-da-EPOCH on B-cell receptor signaling pathway including BTK activity in ARL.

IX. To evaluate the soluble cytokine response to ibrutinib and R-da-EPOCH. X. To characterize the pharmacokinetics of doxorubicin, etoposide, and vincristine in the presence of ibrutinib, and vice versa, and assess the clinical relevance of any drug-drug interaction and correlate with pharmacodynamics outcomes.

OUTLINE: This is a dose escalation study of ibrutinib.

Patients receive rituximab intravenously (IV) on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone orally (PO) daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO once daily (QD) on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim subcutaneously (SC) from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until absolute neutrophil count (ANC) is satisfactory.

After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for up to 5 years.

03

Conditions studied

  • AIDS-Related Lymphoma
  • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have histologically (via at least a core or ideally, incisional or excisional ) documented CD20 positive or negative diffuse large B-cell lymphoma (DLBCL)
  • Tissue available from the diagnostic biopsy in the form of blocks, tissue cores, or slides available for submission to central pathology is required for all participants enrolled to this study, for analysis of integral biomarkers. Formalin-fixed paraffin-embedded tissue from diagnostic tissue is acceptable and recommended; submission of the institutional diagnostic slides is also preferred for all participants enrolled in the study. Tissue and diagnostic slides are required to be submitted within 1 month of enrollment
  • Stage II-IV disease; participant will need by computed tomography (CT) or positron emission tomography (PET) scans if enrolled in the dose-expansion cohort
  • positive; documentation of HIV-1 infection by means of any one of the following:

    • Documentation of HIV diagnosis in the medical record by a licensed health care provider;
    • Documentation of receipt of ART (at least three different medications) by a licensed health care provider (documentation may be a record of an antiretroviral therapy (ART) prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name);
    • HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;
    • Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay
    • NOTE: a "licensed" assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all food drug (IND) studies
  • For the dose-finding cohort participants lymphoma must be untreated. For the dose-expansion cohort participants may have either untreated lymphoma or may have received prior therapy
  • Ages 18 - 64
  • (ECOG) performance status =\< 2 ( >= 50%)
  • For the dose-finding cohort participants must have a ≥ 100 cells/mm\^3. For the dose-expansion cohort participants may have any CD4 count, including a CD4 count \< 100 cells/mm\^3
  • : >= 1,000/mm\^3, unless decreased due to bone marrow involvement with lymphoma
  • : >= 75,000/mm\^3, unless decreased due to bone marrow involvement with lymphoma
  • Total : =\< 1.5 times the institutional (ULN); if potentially due to lymphoma, in the dose-expansion cohort, the first cycle may be given without ibrutinib and if transaminitis and bilirubinemia improves to meet parameters, participant may be enrolled
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]): \< 2 times the institutional ULN; if potentially due to lymphoma, in the dose-expansion cohort, the first cycle will be given without ibrutinib and if transaminitis and bilirubinemia improves to meet parameters, participant may be enrolled
  • Creatinine levels below the normal institutional upper limits; or, >= 50 mL/min/1.73 m\^2 for participants with creatinine levels above institutional normal; unless decreased due to renal involvement by lymphoma
  • Participants must not be on medications, including antiretroviral (ARV) regimens such as cobicistat, indinavir, or ritonavir, or agents with moderate or strong inhibition; if on a moderate or strong CYP3A4 inhibitor regimen prior to study enrollment, participants must be switched to a qualifying regimen with the last dose of the strong CYP3A4 inhibitor taken at least one week before administration of ibrutinib
  • Willingness of sexually active participants to use adequate ; both men and women of treated or enrolled on this study must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry, for the duration of study participation, 90 days after completion of ibrutinib, and 12 months after the last dose of rituximab, whichever comes last; men who only have sex with other men do not need to use contraception specifically for this study (should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately)
  • All participants will be required to be screened for ; all participants who present with acute hepatitis B or show normal transaminases and are hepatitis B surface antigen (HBsAg) positive (+) and IgM+ for hepatitis core antigen will not be eligible for trial enrollment; per Infectious Diseases Society of America (IDSA) and Assistance for AIDS Specific Drugs (AASD) guidelines, those participants that show no immunity, defined by the lack of hepatitis B surface antibody, and show evidence of chronic infection (i.e. hepatitis B [HB]sAg+, HBcore+, hepatitis B surface antibody [HBsAB] negative [-]) will be required to be on anti-hepatitis B therapy, during the study, in order to be eligible; the exact hepatitis B therapy will be at the discretion of the infection disease specialist or investigator; if infected with hepatitis B, participants will be permitted to enroll in the study provided liver function tests meet criteria listed above, there is no evidence of cirrhosis AND participants will be required to be on anti-hepatitis B therapy
  • All participants will be required to be screened for ; if hepatitis C antibody positive, with or without a positive hepatitis C RNA level, participants will be permitted to enroll in the study provided liver function tests meet criteria listed, and have no evidence of cirrhosis; participants diagnosed with hepatitis C less than 6 months from trial enrollment will be considered to have acute hepatitis C, and will be excluded from study UNLESS hepatitis C viral load is undetectable
  • Adequate cardiac function defined as an on echocardiogram (ECHO) or multi-gated acquisition (MUGA) that is at or above the institutional normal limits. For the dose-expansion cohort, if the participant had a pre-treatment ECHO prior to pre-study therapy which reports adequate cardiac function defined as an ejection fraction on ECHO or MUGA that is at or above the institutional normal limits, a repeat ECHO will not need to be repeated prior to start of study treatment
  • Participants must be able to swallow oral pills
  • Ability to understand and willing to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Participants who have had chemotherapy other than R-EPOCH, R-CHOP, or limited therapy, or radiotherapy other than palliative radiation for medical emergencies (like cord compression), within the last 4 weeks
  • For the dose-finding cohort prior cytotoxic chemotherapy or radiotherapy for this lymphoma is exclusionary. For the dose-expansion cohort participants may have received:

    • A maximum of one cycle of combination chemotherapy, including rituximab-containing regimens R-CHOP and R-EPOCH. The start of previous chemotherapy cycle must occur at least 21 days but no more than 28 days prior to beginning treatment under this protocol, and such cycle will count towards the maximum of 6 cycles under this study (i.e., cycle off study will count as cycle 1) OR
    • 1 prior cycle of limited therapy including cyclophosphamide and/or rituximab and/or to improve hepatic or renal function impaired due to lymphoma involvement. The start of this therapy may occur up to 28 days prior to beginning treatment under this protocol; cyclophosphamide administration must have been completed at least 14 days prior to initiation of protocol therapy. Such treatment will not count towards the maximum of 6 cycles under this study (i.e., participants will receive 6 cycles on study)
  • For the dose-finding cohort rituximab within 12 months prior to study registration will be exclusionary; only exception will be if rituximab was given for indications other than the treatment of aggressive lymphoma. For the dose-expansion cohort one cycle of rituximab as part of R-CHOP or R-EPOCH or limited therapy may be administered off study prior to enrollment; prior rituximab will also be allowed if rituximab was given for indications other than the treatment of aggressive lymphoma
  • Participants who are receiving any other agents
  • Participants who have previously received ibrutinib for another indication
  • Expected survival \< 2 months
  • Participants with a history of an opportunistic fungal infection or active fungal infection requiring, or at high risk of requiring, prophylactic or treatment with fluconazole, voriconazole or posaconazole
  • Participants with known from solid tumors should be excluded from this clinical trial
  • Presence of second active tumor, other than non-melanoma skin cancer, carcinoma in situ of the cervix, or Kaposi's sarcoma (KS) that requires systemic therapy
  • For the dose-finding cohort, participants with known or suspected parenchymal brain, spinal cord, prior to study enrollment will be excluded. For the dose-expansion cohort participants with known or suspected parenchymal brain or spinal cord disease, or symptomatic leptomeningeal disease will be excluded. Asymptomatic leptomeningeal disease will be allowed
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinions of the investigator, would limit compliance with study requirements
  • Pregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of ; pregnant women; breastfeeding must be discontinued because of unknown but potential risks in the nursing infant
  • Unable to comply with the requirements of the protocol, or unable to provide adequate in the opinion of the principal investigator
  • Serious, ongoing, non-malignant disease or infection, which in the opinion of the investigator and/or the sponsor would compromise other protocol objectives; participants with active opportunistic infections are ineligible
  • Major surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgery
  • History of cutaneous or mucocutaneous reactions, or diseases in the past, due to any cause, severe enough to cause hospitalization or an inability to eat or drink for > 2 days; this exclusion relates to the long-term possibility of severe cutaneous or mucocutaneous reactions to rituximab that might occur at increased frequency in participants who have had severe skin disease or reactions in the past
  • Myocardial infarction (MI) within 6 months prior to study entry, (NYHA) class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Treatment (R-da-EPOCH)

    Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.

    Drug: Cyclophosphamide · Drug: Doxorubicin Hydrochloride · Drug: Etoposide · Biological: Filgrastim · Drug: Ibrutinib · Other: Laboratory Biomarker Analysis · Biological: Pegfilgrastim · Other: Pharmacological Study · Drug: Prednisone · Biological: Rituximab · Drug: Vincristine Sulfate

Interventions

  • Given IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Frindovyx, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719

  • DrugDoxorubicinStudies of DoxorubicinDoxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex

  • Given IV

    Also known as: Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213

  • BiologicalFilgrastim

    Given SC

    Also known as: Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio

  • Given PO

    Also known as: BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • BiologicalPegfilgrastim

    Given SC

    Also known as: Cegfila, Dulastin, Dyrupeg, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, Grasustek, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-cegf, Pegfilgrastim-dyru, Pegfilgrastim-fpgk, Pegfilgrastim-gras, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegfilgrastim-pelg, Pegfilgrastim-pelm, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, Pelgraz, Pelmeg, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo

  • OtherPharmacological Study

    Correlative studies

  • Given PO

    Also known as: .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone

  • BiologicalRituximab

    Given IV

    Also known as: ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima

  • DrugVincristineStudies of VincristineVincristine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Ibrutinib in Combination With Chemotherapy

    Will be descriptive and will be reported in tabular format with the appropriate summary statistics (count and percentage). In the dose-finding portion, the number of dose limiting toxicities (DLTs) identified among the DLT-evaluable subjects will be listed and summarized by dose level. The safety variables will be listed and summarized for (1) subjects in the dose-finding portion, (2) subjects in the dose expansion cohort (DEC), and (3) all subjects in the study.

    Time frame: Up to 21 days

  2. Recommended Phase II Dose (RP2D) of Ibrutinib in Combination With Chemotherapy

    Will be descriptive and will be reported in tabular format with the appropriate summary statistics (count and percentage). In the dose-finding portion, the number of DLTs identified among the DLT-evaluable subjects will be listed and summarized by dose level. The safety variables will be listed and summarized for (1) subjects in the dose-finding portion, (2) subjects in the DEC, and (3) all subjects in the study.

    Time frame: Up to 21 days

Secondary outcomes

  1. Incidence of Adverse Events Graded Using Common Terminology Criteria for Adverse Events Version 4.0

    Toxicity data will be presented by type and severity for each dose cohort. Incidence of toxicity related dose reductions and treatment discontinuations will be summarized for each dose group.

    Time frame: Up to 5 years

  2. Complete Response Rates

    The complete response rates and their corresponding 95% confidence intervals will be calculated for participants with AIDS-related lymphomas (ARL) treated with combination ibrutinib and rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide and doxorubicin hydrochloride (EPOCH). Response is currently assessed on the basis of clinical, radiologic, and pathologic (i.e., bone marrow) criteria. Radiologic response will be based on the Lugano Classification. Complete metabolic response with Score 1, 2, or 3 with or without a residual mass on 5PS. Partial metabolic response with Score 4 or 5† with reduced uptake compared with baseline and residual mass(es) of any size. Overall Response (OR) consists of complete response and partial response.

    Time frame: Up to 5 years

  3. Progression Free Survival (PFS)

    PFS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals. Progressive disease requires at least 1 of the following Perpendicular diameters: An individual node/lesion must be abnormal with: longest diameter 1.5 cm and Increase by 50% from perpendicular diameters nadir and an increase in longest diameter or shortest diameter from nadir 0.5 cm for lesions 2 cm 1.0 cm for lesions 2 cm. In the setting of splenomegaly, the splenic length must increase by 50% of the extent of its prior increase beyond baseline (e.g., a 15-cm spleen must increase to 16 cm). If no prior splenomegaly, must increase by at least 2 cm from baseline.

    Time frame: 1 year

  4. Progression Free Survival (PFS)

    PFS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals. Progressive disease requires at least 1 of the following Perpendicular diameters: An individual node/lesion must be abnormal with: longest diameter 1.5 cm and Increase by 50% from perpendicular diameters nadir and an increase in longest diameter or shortest diameter from nadir 0.5 cm for lesions 2 cm 1.0 cm for lesions 2 cm. In the setting of splenomegaly, the splenic length must increase by 50% of the extent of its prior increase beyond baseline (e.g., a 15-cm spleen must increase to 16 cm). If no prior splenomegaly, must increase by at least 2 cm from baseline.

    Time frame: 2 years

  5. Overall Survival (OS)

    OS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals.

    Time frame: 1 year

  6. Overall Survival (OS)

    OS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals.

    Time frame: 2 years

  7. Response by Lymphoma Cell-of-origin (COO) Assessment

    Responses are tabulated by gene expression profiling (GEP) (germinal center B-cell \[GCB\], activated B-cell \[ABC\], unclassifiable) and immunohistochemistry \[IHC\] (GCB, non-GCB).

    Time frame: Up to 5 years

  8. Percentage of Participants Who Receive Two or More Cycles of Combination Chemotherapy, and Are Able to Continue on a Minimum Dose Level of Cyclophosphamide of -1 and Above After Dose Adjustments

    Hematologic toxicities will be calculated.

    Time frame: Up to 5 years

  9. Average Number of Days Per Cycle Participants Are Able to Stay on Planned Dose of Ibrutinib

    Average number of days will be calculated.

    Time frame: Up to 5 years

  10. Changes in the Levels of Human Immunodeficiency Virus (HIV)-1 Viral Reservoirs

    Descriptive statistics will be used to evaluate the changes and will be compared with treatment completion. If there are sufficient data, the binomial test of proportions will be used to test if the long term viral reservoir is either undetectable or below baseline in at least half of the participants.

    Time frame: Baseline up to 5 years

  11. Changes in Epstein-Barr Virus (EBV) Viral Loads

    Descriptive statistics will be used to evaluate the changes and compared with treatment completion. If there are sufficient data, the binomial test of proportions will be used to test if the long term viral reservoir is either undetectable or below baseline in at least half of the participants.

    Time frame: Baseline up to 5 years

  12. Effect of Treatment on HIV Latency Reservoirs

    Will be correlated with degree of ITK inhibition and Pearson or Spearman correlation coefficients will be used, as appropriate.

    Time frame: Up to 5 years

  13. Effect of Treatment on B-cell Receptor Signaling Pathway Including BTK Activity

    Descriptive statistics will be used.

    Time frame: Up to 5 years

  14. Effect of Treatment on T-cell Receptor Signaling Via ITK Activity.

    Descriptive statistics will be used.

    Time frame: Up to 5 years

  15. Soluble Cytokine Response to Treatment

    Descriptive statistics will be used.

    Time frame: Up to 5 years

  16. Pharmacokinetics (PK) Parameters Assessment for Ibrutinib, Doxorubicin Hydrochloride, Etoposide, and Vincristine Sulfate

    Relevant individual PK parameters will be estimated using non-compartmental or compartmental PK methods with the software WinNonlin. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) and compared across dose levels (if applicable) using nonparametric statistical testing techniques. PK parameters (i.e., steady state concentration \[Css\], clearance \[Cl\], and area under the curve \[AUC\]) will be correlated with pharmacodynamics effects using nonparametric statistical testing techniques.

    Time frame: Up to 5 years

  17. Survival by Lymphoma Cell-of-origin (COO) Assessment

    Survival rates (PFS and OS at 1 year and 2 years) are reported by gene expression profiling (GEP) (germinal center B-cell \[GCB\], activated B-cell \[ABC\], unclassifiable) and immunohistochemistry \[IHC\] (GCB, non-GCB).

    Time frame: up to 2 years

07

Results

Posted Apr 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneDose-finding CohortDose Expansion Cohort
Started343
Completed340
Not completed03
Withdrew: Withdrawal by subject03

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Ibrutinib in Combination With Chemotherapy

Will be descriptive and will be reported in tabular format with the appropriate summary statistics (count and percentage). In the dose-finding portion, the number of dose limiting toxicities (DLTs) identified among the DLT-evaluable subjects will be listed and summarized by dose level. The safety variables will be listed and summarized for (1) subjects in the dose-finding portion, (2) subjects in the dose expansion cohort (DEC), and (3) all subjects in the study.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Maximum Tolerated Dose (MTD) of Ibrutinib in Combination With Chemotherapy
ParticipantsDose-finding Cohort
No of participants who experience DLTs0
No of participants who do not experience DLTs3
PrimaryRecommended Phase II Dose (RP2D) of Ibrutinib in Combination With Chemotherapy

Will be descriptive and will be reported in tabular format with the appropriate summary statistics (count and percentage). In the dose-finding portion, the number of DLTs identified among the DLT-evaluable subjects will be listed and summarized by dose level. The safety variables will be listed and summarized for (1) subjects in the dose-finding portion, (2) subjects in the DEC, and (3) all subjects in the study.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Recommended Phase II Dose (RP2D) of Ibrutinib in Combination With Chemotherapy
ParticipantsDose-finding Cohort
No of participants who experience DLTs at ibrutinib 560mg0
No of participants who do not experience DLTs at ibrutinib 560mg3
SecondaryIncidence of Adverse Events Graded Using Common Terminology Criteria for Adverse Events Version 4.0

Toxicity data will be presented by type and severity for each dose cohort. Incidence of toxicity related dose reductions and treatment discontinuations will be summarized for each dose group.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondaryComplete Response Rates

The complete response rates and their corresponding 95% confidence intervals will be calculated for participants with AIDS-related lymphomas (ARL) treated with combination ibrutinib and rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide and doxorubicin hydrochloride (EPOCH). Response is currently assessed on the basis of clinical, radiologic, and pathologic (i.e., bone marrow) criteria. Radiologic response will be based on the Lugano Classification. Complete metabolic response with Score 1, 2, or 3 with or without a residual mass on 5PS. Partial metabolic response with Score 4 or 5† with reduced uptake compared with baseline and residual mass(es) of any size. Overall Response (OR) consists of complete response and partial response.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Complete Response Rates
ParticipantsDose-finding CohortDose Expansion Cohort
Complete Response Rates236
SecondaryProgression Free Survival (PFS)

PFS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals. Progressive disease requires at least 1 of the following Perpendicular diameters: An individual node/lesion must be abnormal with: longest diameter 1.5 cm and Increase by 50% from perpendicular diameters nadir and an increase in longest diameter or shortest diameter from nadir 0.5 cm for lesions 2 cm 1.0 cm for lesions 2 cm. In the setting of splenomegaly, the splenic length must increase by 50% of the extent of its prior increase beyond baseline (e.g., a 15-cm spleen must increase to 16 cm). If no prior splenomegaly, must increase by at least 2 cm from baseline.

Time frame:
1 year
Reported as:
Number · percentage of participants
Progression Free Survival (PFS)
percentage of participantsDose-finding CohortDose Expansion Cohort
Progression Free Survival (PFS)33.3 (0.9 to 77.4)89 (73.2 to 95.7)
SecondaryProgression Free Survival (PFS)

PFS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals. Progressive disease requires at least 1 of the following Perpendicular diameters: An individual node/lesion must be abnormal with: longest diameter 1.5 cm and Increase by 50% from perpendicular diameters nadir and an increase in longest diameter or shortest diameter from nadir 0.5 cm for lesions 2 cm 1.0 cm for lesions 2 cm. In the setting of splenomegaly, the splenic length must increase by 50% of the extent of its prior increase beyond baseline (e.g., a 15-cm spleen must increase to 16 cm). If no prior splenomegaly, must increase by at least 2 cm from baseline.

Time frame:
2 years
Reported as:
Number · percentage of participants
Progression Free Survival (PFS)
percentage of participantsDose-finding CohortDose Expansion Cohort
Progression Free Survival (PFS)33.3 (0.9 to 77.4)82.7 (65.4 to 91.9)
SecondaryOverall Survival (OS)

OS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals.

Time frame:
1 year
Reported as:
Number · percentage of participants
Overall Survival (OS)
percentage of participantsDose-finding CohortDose Expansion Cohort
Overall Survival (OS)66.7 (5.4 to 95.8)91.6 (76.1 to 97.2)
SecondaryOverall Survival (OS)

OS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals.

Time frame:
2 years
Reported as:
Number · percentage of participants
Overall Survival (OS)
percentage of participantsDose-finding CohortDose Expansion Cohort
Overall Survival (OS)66.7 (5.4 to 94.5)85 (67.6 to 93.5)
SecondaryResponse by Lymphoma Cell-of-origin (COO) Assessment

Responses are tabulated by gene expression profiling (GEP) (germinal center B-cell \[GCB\], activated B-cell \[ABC\], unclassifiable) and immunohistochemistry \[IHC\] (GCB, non-GCB).

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Response by Lymphoma Cell-of-origin (COO) Assessment
ParticipantsDose-finding CohortDose Expansion Cohort
complete response rate (GCB DLBCL)29
complete response rate (Non-GCB DLBCL)05
complete response rate (Inconclusive/Not done)03
SecondaryPercentage of Participants Who Receive Two or More Cycles of Combination Chemotherapy, and Are Able to Continue on a Minimum Dose Level of Cyclophosphamide of -1 and Above After Dose Adjustments

Hematologic toxicities will be calculated.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Percentage of Participants Who Receive Two or More Cycles of Combination Chemotherapy, and Are Able to Continue on a Minimum Dose Level of Cyclophosphamide of -1 and Above After Dose Adjustments
ParticipantsDose-finding CohortDose Expansion Cohort
Percentage of Participants Who Receive Two or More Cycles of Combination Chemotherapy, and Are Able to Continue on a Minimum Dose Level of Cyclophosphamide of -1 and Above After Dose Adjustments338
SecondaryAverage Number of Days Per Cycle Participants Are Able to Stay on Planned Dose of Ibrutinib

Average number of days will be calculated.

Time frame:
Up to 5 years
Reported as:
Median · Days
Average Number of Days Per Cycle Participants Are Able to Stay on Planned Dose of Ibrutinib
DaysDose-finding CohortDose Expansion Cohort
Average Number of Days Per Cycle Participants Are Able to Stay on Planned Dose of Ibrutinib21 (0 to 21)17 (0 to 21)
SecondaryChanges in the Levels of Human Immunodeficiency Virus (HIV)-1 Viral Reservoirs

Descriptive statistics will be used to evaluate the changes and will be compared with treatment completion. If there are sufficient data, the binomial test of proportions will be used to test if the long term viral reservoir is either undetectable or below baseline in at least half of the participants.

Time frame:
Baseline up to 5 years

Results for this outcome have not been posted.

SecondaryChanges in Epstein-Barr Virus (EBV) Viral Loads

Descriptive statistics will be used to evaluate the changes and compared with treatment completion. If there are sufficient data, the binomial test of proportions will be used to test if the long term viral reservoir is either undetectable or below baseline in at least half of the participants.

Time frame:
Baseline up to 5 years

Results for this outcome have not been posted.

SecondaryEffect of Treatment on HIV Latency Reservoirs

Will be correlated with degree of ITK inhibition and Pearson or Spearman correlation coefficients will be used, as appropriate.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondaryEffect of Treatment on B-cell Receptor Signaling Pathway Including BTK Activity

Descriptive statistics will be used.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondaryEffect of Treatment on T-cell Receptor Signaling Via ITK Activity.

Descriptive statistics will be used.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondarySoluble Cytokine Response to Treatment

Descriptive statistics will be used.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondaryPharmacokinetics (PK) Parameters Assessment for Ibrutinib, Doxorubicin Hydrochloride, Etoposide, and Vincristine Sulfate

Relevant individual PK parameters will be estimated using non-compartmental or compartmental PK methods with the software WinNonlin. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) and compared across dose levels (if applicable) using nonparametric statistical testing techniques. PK parameters (i.e., steady state concentration \[Css\], clearance \[Cl\], and area under the curve \[AUC\]) will be correlated with pharmacodynamics effects using nonparametric statistical testing techniques.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondarySurvival by Lymphoma Cell-of-origin (COO) Assessment

Survival rates (PFS and OS at 1 year and 2 years) are reported by gene expression profiling (GEP) (germinal center B-cell \[GCB\], activated B-cell \[ABC\], unclassifiable) and immunohistochemistry \[IHC\] (GCB, non-GCB).

Time frame:
up to 2 years
Reported as:
Number · percentage of participants
Survival by Lymphoma Cell-of-origin (COO) Assessment
percentage of participantsDose-finding CohortDose Expansion Cohort
1-yr PFS (GCB DLBCL)50 (0.6 to 91)94.4 (66.6 to 99.2)
1-yr PFS (non-GCB DLBCL)—83.9 (49.4 to 95.7)
1-yr PFS (Inconclusive/Not done)0 (0 to 0)80 (20.4 to 96.9)
2-yr PFS (GCB DLBCL)50 (0.6 to 91)88.1 (60.2 to 96.9)
2-yr PFS (non-GCB DLBCL)—75.5 (41.6 to 91.4)
2-yr PFS (Inconclusive/not done)0 (0 to 0)80 (20.4 to 96.9)
1-yr OS (GCB DLBCL)50 (0.6 to 91)100 (100 to 100)
1-yr OS (non-GCB DLBCL)—83.9 (49.4 to 95.7)
1-yr OS (Inconclusive/not done)100 (100 to 100)80 (20.4 to 96.9)
2-yr OS (GCB DLBCL)50 (0.6 to 91)87.5 (58.6 to 96.7)
2-yr OS (non-GCB DLBCL)—86.9 (49.4 to 95.7)
2-yr OS (Inconclusive/not done)100 (100 to 100)80 (20.4 to 96.9)

Adverse events

Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose-finding Cohort2/3 (66.7%)3/3 (100%)3/3 (100%)
Dose Expansion Cohort6/40 (15%)21/40 (52.5%)38/40 (95%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventDose-finding CohortDose Expansion Cohort
AnemiaBlood and lymphatic system disorders3/30/40
Disease ProgressionGeneral disorders2/32/40
HypokalemiaMetabolism and nutrition disorders2/30/40
Febrile NeutropeniaBlood and lymphatic system disorders1/34/40
BacteremiaInfections and infestations1/30/40
DehydrationMetabolism and nutrition disorders1/30/40
HypocalcemiaMetabolism and nutrition disorders1/30/40
hypokalemiaMetabolism and nutrition disorders1/30/40
Acute Kidney InjuryRenal and urinary disorders1/30/40
Pelvic PainReproductive system and breast disorders1/30/40
Most frequent other events
Showing 10 of 39
Most frequent other events
EventDose-finding CohortDose Expansion Cohort
AnemiaBlood and lymphatic system disorders3/327/40
HypokalemiaMetabolism and nutrition disorders3/315/40
NauseaGastrointestinal disorders2/316/40
ConstipationGastrointestinal disorders2/312/40
HypomagnesemiaMetabolism and nutrition disorders2/34/40
Platelet Count DecreasedInvestigations0/323/40
Neutrophil Count DecreasedInvestigations0/321/40
White Blood Cell DecreasedInvestigations1/321/40
Peripheral Sensory neuropathyNervous system disorders0/315/40
HeadacheNervous system disorders0/314/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dose-finding CohortDose Expansion CohortTotal
Median47 (32 to 63)53 (24 to 64)52 (24 to 64)
Age, Customized
Age, Customized(Participants)Dose-finding CohortDose Expansion CohortTotal
Age, Categorized — <40 years old11011
Age, Categorized — 40-60 years old12627
Age, Categorized — >60 years old145
Sex: Female, Male
Sex: Female, Male(Participants)Dose-finding CohortDose Expansion CohortTotal
Female178
Male23335
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose-finding CohortDose Expansion CohortTotal
Hispanic or Latino01212
Not Hispanic or Latino32831
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose-finding CohortDose Expansion CohortTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American21921
White11718
More than one race000
Unknown or Not Reported044
Region of Enrollment
Region of Enrollment(participants)Dose-finding CohortDose Expansion CohortTotal
United States34043
Lymphoma subtype
Lymphoma subtype(Participants)Dose-finding CohortDose Expansion CohortTotal
GCB DLBCL21820
Non-GCB DLBCL01717
Inconclusive/Not done156
08

Study locations

19 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Oct 2024, 78 months.

Results were first posted in Apr 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2017
First posted
Jul 18, 2017
StartActual
Mar 16, 2018
Primary completionActual
Oct 10, 2024
CompletionEst.
Jul 16, 2027
Results first posted
Apr 2, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03220022
Responsible party
Sponsor
First posted
Jul 18, 2017
Start date
Mar 16, 2018
Primary completion
Oct 10, 2024
Completion
Jul 16, 2027 (estimated)
Results posted
Apr 2, 2026
Last update
Nov 18, 2026

Study contacts

Ida C Wong-Sefidan
principal investigator · AIDS Malignancy Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Doxorubicin · Etoposide · Ibrutinib · Prednisone · Rituximab · Vincristine

Start the discussion